Related Experiment Video
Updated: Aug 18, 2026
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Current trials in multiple sclerosis: established evidence and future hopes
Joep Killestein1, Chris H Polman
1Department of Neurology, MS Centre, VU Medical Centre Amsterdam, Amsterdam, The Netherlands.
Purpose Of Review:
The aim of the present report is to briefly review multiple sclerosis therapeutic trials published or presented in 2004 to provide an up-to-date overview of the established evidence and new insights.
Recent Findings:
New data have come available that help us understand how currently approved disease modifying drugs can best be used. Nonetheless, their limited effectiveness - especially in progressive forms of multiple sclerosis - as well as the inconvenience and toxicity associated with their use, emphasize the need for new treatment strategies. A substantial number of reports on new emerging treatment modalities were published in 2004, and one of these modalities was newly approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis.
Summary:
Further advances have been made in the treatment of multiple sclerosis patients. On the one hand, we know better how and in whom to use existing medications. On the other hand, it is exciting to witness how increased insight in the pathophysiology of the disease and its symptoms has led to a series of new, innovative treatment modalities.
Insights
Reviewing 2004 multiple sclerosis trials reveals improved use of existing therapies and exciting new treatment options. Advances in understanding pathophysiology are driving innovative therapeutic strategies for multiple sclerosis patients.
Area of Science:
- Neurology
- Immunology
- Clinical Trials
Background:
- Current disease-modifying drugs for multiple sclerosis (MS) show limited effectiveness, particularly in progressive forms.
- Inconvenience and toxicity of existing MS therapies necessitate novel treatment strategies.
- Understanding MS pathophysiology is crucial for developing new treatments.
Purpose of the Study:
- To review multiple sclerosis (MS) therapeutic trials published or presented in 2004.
- To provide an updated overview of established evidence and new insights in MS treatment.
- To highlight advancements in understanding and treating MS.
Main Methods:
- Review of therapeutic trials for multiple sclerosis (MS) from 2004.
- Analysis of published and presented data on MS treatments.
- Synthesis of information on established and emerging MS therapies.
Main Results:
- New data enhance understanding of optimal use for approved disease-modifying drugs in multiple sclerosis (MS).
- A new treatment modality was approved by the US Food and Drug Administration (FDA) for relapsing forms of MS.
- Numerous reports on emerging treatment modalities for MS were published in 2004.
Conclusions:
- Significant advances have been made in multiple sclerosis (MS) treatment.
- Improved knowledge guides the application of existing MS medications.
- Increased insight into MS pathophysiology fuels innovative therapeutic approaches.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...